Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Affordable: Flat rate of $75/weekno hidden fees or surprise charges
Innovent moved quickly through the Chinese regulatory process and brought mazdutide to market faster than most Western pharmaceutical timelines would allow
Efficacy and safety of once-weekly semaglutide versus sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
Why it matters: Novo has struggled to stay competitive with Eli Lilly LLY in developing the next generation of obesity drugs that could improve on Lillys Zepbound, with disappointing data for phase 2 drug monlunabant in September and phase 3 GLP-1 and amylin combination cagrisema in December
Moreover, it's encouraging to see that many individuals who have previously struggled with their weight have found Wegovy to be truly effective
No therapy is right for everyone
